

1 **Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming**

2

3 R.S.G. Sablerolles MD^{1,2}, W.J.R. Rietdijk PhD², A. Goorhuis MD PhD^{3,4}, D.F. Postma MD PhD⁵, Prof. L.G.
4 Visser⁶, D. Geers Msc⁷, K.S. Schmitz MSc⁷, H.M. Garcia Garrido MD³, Prof. M.P.G. Koopmans⁷,
5 V.A.S.H. Dalm MD PhD⁸, N.A. Kootstra PhD⁹, Prof. A.L.W. Huckriede¹⁰, M. Lafeber MD PhD¹, Prof. D.
6 van Baarle^{10,11}, C.H. GeurtsvanKessel MD PhD^{7,†}, R.D. de Vries, PhD^{7,†}, Prof. P.H.M. van der Kuy^{2,†,*} on
7 behalf of the SWITCH research group

8

9 ¹Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

10 ²Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands

11 ³Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam
12 University Medical Centers, Amsterdam, the Netherlands

13 ⁴Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the
14 Netherlands

15 ⁵Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen,
16 Groningen, the Netherlands

17 ⁶Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

18 ⁷Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands

19 ⁸Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of
20 Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands

21 ⁹Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam
22 Infection and Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands

23 ¹⁰Department of Medical Microbiology and Infection Prevention, University Medical Center
24 Groningen, University of Groningen, Groningen, the Netherlands

25 ¹¹Center for Infectious Disease Control, National Institute for Public Health and the Environment,
26 Bilthoven, the Netherlands

27

28 † contributed equally

29

30 * Corresponding author: P.H.M. van der Kuy, Department of Hospital Pharmacy, Erasmus University
31 Medical Center, Rotterdam, 3015 GD, the Netherlands. E-mail: h.vanderkuy@erasmusmc.nl.

32 **Abstract**

33

34 **Background.** In face of the developing COVID-19 pandemic with a need for rapid and practical
35 vaccination strategies, Ad26.COVS.2.S was approved as single shot immunization regimen. While
36 effective against severe COVID-19, Ad26.COVS.2.S vaccination induces lower SARS-CoV-2-specific
37 antibody levels compared to its mRNA-based counterparts. To support decision making on the need
38 for booster vaccinations in Ad26.COVS.2.S-primed individuals, we assessed the immunogenicity and
39 reactogenicity of homologous and heterologous booster vaccinations in Ad26.COVS.2.S-primed health
40 care workers (HCWs).

41

42 **Methods.** The SWITCH trial is a single-(participant)-blinded, multi-center, randomized controlled trial
43 among 434 HCWs who received a single Ad26.COVS.2.S vaccination. HCWs were randomized to no
44 boost, Ad26.COVS.2.S boost, mRNA-1273 boost, or BNT162b2 boost. We assessed the level of SARS-
45 CoV-2-specific binding antibodies, neutralizing antibodies against infectious virus, SARS-CoV-2-
46 specific T-cell responses, and reactogenicity.

47

48 **Results.** Homologous and heterologous booster vaccinations resulted in an increase in SARS-CoV-2-
49 specific binding antibodies, neutralizing antibodies and T-cell responses when compared to single
50 Ad26.COVS.2.S vaccination. In comparison with the homologous boost, the increase was significantly
51 larger in heterologous regimens with the mRNA-based vaccines. mRNA-1273 boosting was most
52 immunogenic, associated with higher reactogenicity. Only mild to moderate local and systemic
53 reactions were observed on the first two days following booster.

54

55 **Conclusions.** Boosting of Ad26.COVS.2.S-primed HCWs was well-tolerated and immunogenic.
56 Strongest responses were detected after boosting with mRNA-based vaccines. Based on our data,
57 efficacy on infection and transmission of boosters is expected. In addition to efficacy, decision
58 making on boost vaccinations should include timing, target population, level of SARS CoV-2
59 circulation, and the global inequity in vaccine access.

60

61 **Trial registration.** Funded by ZonMW (10430072110001); ClinicalTrials.gov number, NCT04927936.

62 Introduction

63 Four COVID-19 vaccines are currently authorized for use in the European Union: two mRNA-based
64 (BNT162b2 ['Comirnaty', Pfizer-BioNTech], mRNA-1273 ['Spikevax', Moderna]), and two adenovirus
65 vector-based (ChAdOx1 nCoV-19 ['Vaxzevria', AstraZeneca], and Ad26.COV2.S ['Janssen']).
66 Immunization with these vaccines prevents mild to severe COVID-19 with high efficacy ¹⁻⁴.
67 BNT162b2, mRNA-1273 and ChAdOx1 nCoV-19 are administered in homologous prime-boost
68 regimens with different intervals, whereas Ad26.COV2.S is intended as a single-dose. The durability
69 of protection and potential need for boosts is under continuous assessment.

70

71 The single-dose regimen and favorable storage conditions of Ad26.COV2.S provides major
72 advantages in deployment ³. Additionally, both humoral and cellular immune responses are
73 effectively induced, and persist up to 8 months after Ad26.COV2.S vaccination ^{5,6}. However, in head-
74 to-head comparisons, the mRNA-based vaccines induce higher levels of spike (S)-specific antibodies,
75 and are superior to Ad26.COV2.S in vaccine efficacy (VE) against infection and mild disease ^{7,8}.
76 Notably, the difference in VE against hospitalization after Ad26.COV2.S or mRNA-based vaccination
77 is smaller, probably in part attributed to immunological correlates like T-cell responses. Recent
78 studies on homologous Ad26.COV2.S booster vaccination at 56 or 180 days after the primary
79 vaccination showed an increase in binding antibody levels ⁶ but did not study effects on T-cell
80 immunity, whereas this may play an important role in protecting against severe disease.

81

82 'Mixing & matching' different COVID-19 vaccines has the benefit of enhanced flexibility of
83 vaccination campaigns ⁹, and the potential induction of broader immune responses ¹⁰⁻¹⁴.
84 Heterologous vaccination regimens with ChAdOx1 nCoV-19 and BNT162b2 were previously
85 demonstrated to be safe and to induce comparable or even superior immune responses than
86 homologous boosting ¹⁵⁻¹⁸. Complete immunological and safety assessments on the effect of mRNA-
87 boosters in Ad26.COV2.S-primed individuals have not yet been performed ¹⁹, but are highly relevant
88 as millions of individuals have been immunized with this vaccine.

89

90 To support decision making regarding booster vaccinations in Ad26.COV2.S-primed individuals, we
91 performed a head-to-head comparison in Ad26.COV2.S-primed HCWs of a homologous booster
92 vaccination and heterologous boosting with mRNA-based vaccines BNT162b2 or mRNA-1273. A
93 complete immunological assessment was performed, including the measurement of neutralizing
94 antibodies and SARS-CoV-2-specific T-cell responses.

95 **Methods**

96

97 **Ethical statement**

98 The SWITCH trial is a single-(participant)-blinded, multi-center, randomized controlled trial among
99 434 healthy health care workers (HCWs) performed in four academic hospitals in the Netherlands
100 (Amsterdam University Medical Center, Erasmus University Medical Center, Leiden University
101 Medical Center, and University Medical Center Groningen) according to the previously described
102 protocol ⁹. The trial adheres to the principles of the Declaration of Helsinki and was approved by the
103 Medical Research Ethics Committee from Erasmus Medical Center (MEC 2021-0132) and the local
104 review boards of the other participating centers. All participants provided written informed consent
105 before enrollment.

106

107 **Participants and randomization**

108 HCWs between 18 and 65 years of age without severe comorbidities, and no known history of SARS-
109 CoV-2 infection (either laboratory-confirmed or self-reported) were eligible ⁹. All participants were
110 primed with the Ad26.CO2.S vaccine 3 months before enrollment and were randomized in one of
111 the following groups; Ad26.CO2.S/no boost, Ad26.CO2.S/Ad26.CO2.S, Ad26.CO2.S/mRNA-
112 1273, or Ad26.CO2.S/BNT162b2. Participants were assigned to study groups in a 1:1:1:1 fashion;
113 randomization was stratified by study site after obtaining written informed consent.

114

115 **Study design**

116 Ad26.CO2.S-primed HCWs received a booster vaccination at study visit 1 (day 0) by injection in the
117 deltoid muscle. The prime-boost interval was 84 days (-7 days / +21 days). Participants were blinded
118 to the allocated vaccine by applying blinded etiquettes to conceal volume and appearance. The
119 vaccines were administered according to the Summary of Product Characteristics. HCWs randomized
120 to the Ad26.CO2.S/no boost group were informed of their allocation at study visit 1, and did not
121 receive a placebo injection. Blood samples were collected at the timepoint of study visit 1 and 2 (0
122 and 28 days). Participants were unblinded for the booster vaccination by e-mail eight days after
123 injection, after completing the reactogenicity questionnaires.

124

125 **Safety assessments**

126 Safety assessments included monitoring of self-reported local and systemic reactions after the
127 Ad26.CO2.S priming vaccination and different booster vaccinations by use of a modified 4-point US
128 Food and Drug administration toxicity scale (0=no complaints, 1=mild complaints, does not interfere

129 with daily activities, 2=moderate, interfere with daily activities or 3=severe, daily activities are no
130 longer possible)²⁰. Participants filled in electronic questionnaires retrospectively, \pm 84 days after the
131 initial priming vaccination (all participants) and prospectively 7 days following the booster
132 vaccination. Serious adverse events and solicited local or systemic reactions were self-reported
133 (either through the questionnaire, by e-mail, or by phone). Safety monitoring (blood biochemistry
134 and hematology assessment) was performed at days 0 and 28.

135

136 **Analyses of humoral and cellular immunity**

137 The analysis of humoral and cellular immune responses is described in detail in the **Supplementary**
138 **Material**. Briefly, SARS-CoV-2 nucleocapsid (N)-specific antibodies were measured to confirm that
139 participants had not been previously exposed to SARS CoV-2. Spike (S)-specific binding antibodies
140 were measured at 0 and 28 days after the booster vaccination using a quantitative anti-spike IgG
141 assay (Liaison SARS-CoV-2 TrimericS IgG assay, DiaSorin, Italy)^{21,22}. Neutralizing capacity of
142 antibodies against infectious SARS CoV-2 D614G was assessed in a plaque reduction neutralization
143 test (PRNT) on Vero-E6 cells. SARS-CoV-2-specific T-cell responses were assessed by IFN- γ Release
144 Assay (IGRA, QuantiFERON, Qiagen) at day 0 and 28 after booster vaccination as previously
145 described²³.

146

147 **Statistical analysis**

148 All statistical analyses are described in the **Supplementary Material**.

149 **Results**

150

151 **Baseline characteristics**

152 697 HCWs were screened for eligibility, of whom 461 were randomized for a booster vaccination; 27
153 individuals were excluded from further analyses (**Figure 1**). All randomized HCWs included in the per
154 protocol analysis (n=434) had their first study visit within the pre-defined period of 84 days (-7 and
155 +21 days) and adhered to the timing between study visits (**Table 1**). The final sample consisted of
156 280 (64.7%) women and 153 (35.3%) men with a median age of 40 years (IQR:30-50) and a median
157 BMI of 23.9 (IQR 21.6-26.6). Baseline characteristics were not different between groups (**Table 1**). At
158 baseline, there were no significant differences with respect to S-specific IgG binding antibodies
159 (p=0.39), neutralizing antibodies (p=0.55), and SARS-CoV-2-specific T-cell responses (p=0.92) across
160 groups (**Figure 2A, 2C, 3A**).

161

162 **Rapid recall of S-specific antibodies in primed HCWs after booster vaccination**

163 Levels of anti-S1 IgG binding antibodies were determined pre- and post-booster vaccination (days 0
164 and 28) by a quantitative assay (**Figure 2A, B**). Based on a test cut-off for positivity at 33.8 BAU/ml
165 (as per manufacturer's instructions), 389 of 434 Ad26.COVID.S-primed HCWs had detectable S-
166 binding antibodies at baseline (3 months after prime, 89.6% responders). We found no significant
167 differences in percentage of participants without detectable binding antibodies across groups
168 (p=0.75), with 12.4%, 8.4%, 11.6%, and 9% for no boost, Ad26.COVID.S boost, mRNA-1273 boost, and
169 BNT162b2 boost, respectively.

170

171 Booster vaccinations led to a significant increase in S-specific binding antibodies in all groups
172 compared to baseline levels (p<0.001 in all groups, **Figure 2A**). When an increase in antibody levels
173 was calculated as a per participant fold change (dividing post-boost by pre-boost levels), boosting
174 with either Ad26.COVID.S, mRNA-1273, or BNT162b2 led to a significant increase in antibodies
175 compared to the Ad26.COVID.S single shot regimen (p<0.001 in all groups, **Figure 2B**). Notably, the
176 heterologous mRNA-based booster vaccinations resulted in significantly higher binding antibody
177 levels than homologous boost with Ad26.COVID.S (p<0.001), with mRNA-1273 performing slightly
178 better than BNT162b2 (p=0.01). Booster vaccination with heterologous mRNA-based vaccines also
179 led to a 100% response rate, whereas 3 of 106 participants in the Ad26.COVID.S boost group
180 remained below the test cut-off for presence of binding antibodies.

181 **Neutralizing antibodies increase after homologous or heterologous booster vaccination**

182 In addition to binding antibodies, SARS-CoV-2-specific neutralizing antibodies were measured by an
183 infectious virus PRNT in participants from one academic center (Erasmus MC, N=213) (**Figure 2C,**
184 **Supplementary Figure 1**). Based on a test cut-off for positivity at 28.6 IU/ml (corresponding to a
185 serum dilution of 1:40), 158 of 213 Ad26.COVID.S-primed HCWs had detectable neutralizing
186 antibodies at baseline (3 months after prime, 74.2%); participants without detectable vaccine-
187 induced neutralizing antibodies were equally divided over the study groups (24.1% no boost, 27.5%
188 Ad26.COVID.S boost, 24.1% mRNA-1273 boost, and 27.8% BNT162b2 boost; $p=0.95$).

189

190 Booster vaccinations led to a significant increase in neutralizing antibodies in all groups compared to
191 baseline levels ($p<0.001$ in all groups). After booster vaccination with any of the vaccines,
192 neutralizing antibody levels in participants without detectable pre-booster neutralization were
193 increased to above detection level with 1 exception in the Ad26.COVID.S boost group. Overall,
194 heterologous mRNA-based booster vaccination increased neutralizing antibodies to higher levels
195 when compared to Ad26.COVID.S booster vaccination (**Figure 2C, Supplementary Figure 1**).

196

197 **S-specific binding antibodies correlate to the presence of neutralizing antibodies**

198 By performing a linear regression analysis on log-transformed binding and neutralizing antibody
199 levels in pre-boost sera ($Y=2.89*X-0.498$), we were able to determine that the two are strongly
200 correlated (Spearman $R = 0.83$, $p < 0.001$) and that a binding antibody level of >68.3 BAU/ml
201 correlates to the presence of neutralizing antibodies (>28.6 IU/ml) (**Figure 2D**). Re-analyzing the
202 entire cohort for the presence of neutralizing antibodies with this arbitrary cut-off set at 68.3
203 BAU/ml indicated that 308 of 434 Ad26.COVID.S-primed HCW potentially had neutralizing antibodies
204 at baseline, corresponding to 71.0%. Homologous booster vaccination increased neutralization
205 response rate to 95.2%, whereas heterologous mRNA-based booster vaccination led to a 100%
206 response rate regarding neutralizing antibodies.

207

208 **Rapid recall of T-cell responses in primed HCWs after booster vaccination**

209 SARS-CoV-2-specific T-cell responses were measured pre- and post-booster vaccination (days 0 and
210 28) in whole blood at 3 participating centers in a random selection of samples (N=182) (**Figure 3A, B,**
211 **Supplementary Figure 2**). Using a peptide pool covering the S protein (Ag2, Qiagen) and based on a
212 test cut-off for positivity at 0.15 IU IFN- γ /ml assessed by IGRA (per manufacturer's instructions), 119
213 of 182 Ad26.COVID.S-primed HCWs had detectable T-cell responses at baseline.

214 Booster vaccinations led to a rapid recall of T-cell responses in all groups compared to baseline levels
215 ($p=0.001$ for Ad26.COVS boost, $p<0.001$ for mRNA-based boost) (**Figure 3A**). When an increase in
216 T-cell responses was calculated as a per participant fold change, boosting with either Ad26.COVS,
217 mRNA-1273, or BNT162b2 led to a significant increase in T-cells compared to the Ad26.COVS single
218 shot regimen ($p<0.001$ in all groups, **Figure 3B**). Notably, heterologous booster vaccination with
219 mRNA-1273 resulted in significantly higher T-cell responses than the homologous boost ($p<0.001$),
220 but BNT162b2 booster vaccination did not. In terms of response rate, both mRNA-1273 and
221 BNT162b2 boost (91.7% and 91.5% response rate, respectively) performed better than homologous
222 Ad26.COVS boost (72.7%). Similar trends were observed with two other peptide pools (Ag1:
223 receptor binding domain-specific T-cells, Ag3: S and other structural proteins, **Supplementary Figure**
224 **2**). SARS-CoV-2-specific T-cell responses significantly correlated to the presence of S-specific binding
225 antibodies (**Supplementary Figure 3**).

226

227 **Reactogenicity**

228 Reactogenicity data (severity and duration) retrospectively collected on the prime with Ad26.COVS
229 is provided in **Supplementary Table 1 and 2**. Reactogenicity data (severity and duration)
230 prospectively collected during seven days following the booster vaccination indicated increased
231 severity of local (pain, redness, and swelling at injection site) and systemic (chills, fever, and muscle
232 ache) reactions after heterologous booster vaccination with mRNA-1273 as compared to the other
233 vaccination regimens (all $p < 0.01$, **Figure 4**, actual data in **Supplementary Table 3 and 4**). The
234 difference between regimens was most prominent on the day of boost and day 1 after vaccination
235 ($p<0.01$). All adverse events were mild to moderate, did not require hospitalization, and symptoms
236 generally disappeared within 48 hours, indicating that both homologous and heterologous regimens
237 were well-tolerated.

238 Discussion

239 In the SWITCH trial, we examined the immunogenicity and reactogenicity of homologous and
240 heterologous booster vaccination regimens in previously Ad26.COV2.S-primed HCW, and compared
241 these regimens to the approved Ad26.COV2.S single shot regimen. Both homologous and
242 heterologous booster vaccinations led to an increase in SARS-CoV-2-specific binding antibodies,
243 neutralizing antibodies and T-cell responses, but the increase was most prominent in heterologous
244 regimens with mRNA-based COVID-19 vaccines mRNA1273 and BNT162b2.

245

246 Protection against a severe clinical course of COVID-19 with the currently approved Ad26.COV2.S
247 single shot regimen is high ³, and it was recently reported that vaccination-induced immune
248 responses can stably be detected up to 8 months post vaccination ⁵. However, in comparison to the
249 mRNA-based vaccines approved in Europe, antibody responses induced by Ad26.COV2.S are lower
250 than responses to mRNA-based vaccines, which raises the questions if booster vaccinations might be
251 necessary to protect against currently and possibly future circulating SARS-CoV-2 variants of concern
252 (VOC) that partially evade antibody responses such as the Beta and Delta variants ^{7,8,24}.

253

254 A first aspect to evaluate is the safety of booster vaccinations. Heterologous ‘mixing and matching’
255 of approved vaccines has not been evaluated in phase 3 clinical trials, meaning that safety and
256 reactogenicity of these vaccination regimens should be strictly evaluated in post-licensure studies.
257 We did not observe any serious adverse events in this study; however, the sample size and study
258 period is too small to observe the prevalence of rare adverse events. Potentially correlated to
259 stronger boosting of immune responses, we found that mRNA1273-boosted participants perceived
260 more mild local and systemic reactions. This suggests that mixing and matching Ad26.COV2.S with
261 mRNA-based vaccines is safe and well-tolerated, as described by others ^{18,19}.

262

263 The next step in decision making on the necessity of booster vaccinations is identifying a correlate of
264 protection. Although well-defined correlates of protection against SARS CoV-2 infection have not yet
265 been defined ²⁵, neutralizing antibodies were shown to play an important role ²⁶. A challenge is that
266 assays to measure these responses are not standardized, making data from individual studies
267 difficult to compare. Therefore, we propose an arbitrary cut-off of binding IgG antibodies that
268 directly correlates to neutralizing capacity against D614G in Ad26.COV2.S-vaccinated individuals
269 (68.3 BAU/ml), based on validation studies with an NIBSC reference standard and studies in COVID-
270 19 patients ²⁷⁻²⁹. By doing so, we were able to combine the advantages of standardized high
271 throughput analyses for binding antibodies with the biologically relevant measure of functional

272 antibodies that inhibit binding of SARS-CoV-2 to host cells. By using this surrogate binding cut-off for
273 neutralization, we determined that 71.0% of participants already had neutralizing antibodies against
274 SARS-CoV-2 after a single Ad26.COVS injection. However, boosting significantly increased the
275 levels. In this study, we measured neutralization of D614G, which is close to the virus used for
276 development of the approved adenovirus- and mRNA-based vaccines, to specifically focus on vaccine
277 responses. Based on published information on cross-neutralization of variants, higher neutralizing
278 titers might be required to protect against (future) VOC.

279

280 In addition to antibody responses, induction and boosting of SARS CoV-2-specific T cells should be
281 part of overall immunological assessments³⁰. Here, we show that SARS-CoV-2-specific T-cells were
282 detectable in only 65.8% of Ad26.COVS-primed participants 3 months post vaccination. Especially
283 boosting with mRNA-based vaccines led to a rapid increase in SARS-CoV-2-specific T-cells (100%
284 response rate), indicating that immunity formed by the priming vaccination could rapidly be recalled
285 by boosting. It was previously shown that SARS-CoV-2-specific T-cells equally recognize different
286 variants of concern³¹, and therefore especially the induction of T-cells is important in face of waning
287 antibody levels and circulation of SARS-CoV-2 variants.

288

289 A potential limitation of our study is that we have exclusively evaluated booster vaccinations in
290 young HCWs without severe comorbidities, and we may not be able translate these results to other
291 populations. However, previous studies on homologous vaccination regimens show similar
292 immunogenicity data comparing younger (18–55 years) and older (>55 years) adults³²⁻³⁴.
293 Furthermore, we evaluated the heterologous booster vaccination regimens in a three-month
294 interval from the priming vaccination, to allow a comparison with ChAdOx1 nCoV-19 trials³⁵, but the
295 optimal prime-boost interval remains to be investigated. The homologous prime-boost intervals in
296 the Ad26.COVS trials published after inception of the SWITCH trial varied from 2 to 6 months^{6,36},
297 and suggest that late boosting might be more effective. This would further enhance the effect
298 observed in our study.

299

300 In conclusion, single dose Ad26.COVS vaccination adequately primes the immune system. We now
301 show that in face of possible waning immunity and circulation of SARS-CoV-2 variants, these
302 responses can be boosted most efficiently with mRNA vaccines. Upon boosting, an increased VE
303 against infection and transmission is likely, but future studies will need to show the added value of
304 boosting on VE against severe disease. Discussion on the need for booster vaccination should also

305 consider timing, the target population, the level of SARS CoV-2 circulation, and the global inequity in
306 vaccine access.

307 References

- 308 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
309 Covid-19 Vaccine. *N Engl J Med* 2020;383:2603-15.
- 310 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
311 CoV-2 Vaccine. *N Engl J Med* 2021;384:403-16.
- 312 3. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
313 Vaccine against Covid-19. *N Engl J Med* 2021.
- 314 4. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1
315 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
316 controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021: 99–111.
- 317 5. Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune
318 responses 8 months after Ad26. COV2. S vaccination. *N Engl J Med* 2021;385:951-3.
- 319 6. Sadoff J, Le Gars M, Cardenas V, et al. Durability of antibody responses elicited by a
320 single dose of Ad26.COV2.S and substantial increase following late boosting. *medRxiv*
321 2021:2021.08.25.21262569.
- 322 7. van Gils MJ, Lavell AHA, van der Straten K, et al. Four SARS-CoV-2 vaccines induce
323 quantitatively different antibody responses against SARS-CoV-2 variants. *medRxiv*
324 2021:2021.09.27.21264163.
- 325 8. Collier AY, Yu J, McMahan K, et al. Differential Kinetics of Immune Responses Elicited
326 by Covid-19 Vaccines. *N Engl J Med* 2021.
- 327 9. Sablerolles RSG, Goorhuis A, GeurtsvanKessel C, et al. Heterologous Ad26.COV2.S
328 Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
329 *Front Immunol* 2021.
- 330 10. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al. Heterologous vaccination
331 regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune
332 responses in mice. *Nat Commun* 2021;12:2893.
- 333 11. He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective
334 immune response bottleneck of COVID-19 vaccine candidates. *Emerging Microbes &*
335 *Infections* 2021;10:629-37.
- 336 12. Duarte-Salles T, Prieto-Alhambra D. Heterologous vaccine regimens against COVID-
337 19. *The Lancet* 2021;398:94-5.
- 338 13. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-
339 CoV-2 variants. *N Engl J Med* 2021;384:2212-8.
- 340 14. Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 Variants and Vaccines. *N Engl J*
341 *Med* 2021.
- 342 15. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus
343 homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19
344 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *The Lancet*
345 2021;398:856-69.
- 346 16. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of
347 homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and
348 BNT162b2: a prospective cohort study *Lancet Respir Med* 2021.
- 349 17. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of
350 BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-
351 label, randomised, controlled, phase 2 trial. *The Lancet* 2021;398:121-30.
- 352 18. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous
353 prime-boost COVID-19 vaccination: initial reactogenicity data. *The Lancet* 2021;397:2043-6.

- 354 19. Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 Booster
355 Vaccinations: Preliminary Report. medRxiv 2021:2021.10.10.21264827.
- 356 20. Food and Drug Administration (FDA). Toxicity grading scale for healthy adults and
357 adolescent volunteers enrolled in preventive vaccine clinical trials. Available from:
358 <https://www.fda.gov/media/73679/download> [accessed 1st April 2021].
- 359 21. Mahmoud SA, Ganesan S, Bissar S, Zaher W. Evaluation of serological tests for
360 detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status.
361 medRxiv 2021.
- 362 22. Leuzinger K, Osthoff M, Dräger S, et al. Comparing immunoassays for SARS-
363 Coronavirus-2 antibody detection in patients with and without laboratory-confirmed SARS-
364 Coronavirus-2 infection. J Clin Microbiol 2021;JCM0138121.
- 365 23. Sanders J-S, Bemelman FJ, Messchendorp AL, et al. The RECOVAC Immune-Response
366 Study The immunogenicity, tolerability and safety of COVID-19 vaccination in patients with
367 chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation
368 2021;forthcoming.
- 369 24. Rishi RG, Mark MP, Sokratis AA, et al. mRNA vaccines induce durable immune
370 memory to SARS-CoV-2 and variants of concern. Science;0:eabm0829.
- 371 25. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
372 Nature medicine 2021;27:1147-8.
- 373 26. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
374 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine
375 2021:1-7.
- 376 27. van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of
377 infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).
378 Nat Commun 2021;12:267.
- 379 28. Okba NMA, Muller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus
380 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis
381 2020;26:1478-88.
- 382 29. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological
383 assays informs future diagnostics and exposure assessment. Nat Commun 2020;11:3436.
- 384 30. Tan AT, Lim JME, Le Bert N, et al. Rapid measurement of SARS-CoV-2 spike T cells in
385 whole blood from vaccinated and naturally infected individuals. The Journal of Clinical
386 Investigation 2021;131.
- 387 31. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially
388 escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
389 Science Immunology 2021.
- 390 32. Anderson EJ, Roupshael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-
391 2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 2020;383:2427-38.
- 392 33. Walsh EE, Frenck Jr RW, Falsey AR, et al. Safety and immunogenicity of two RNA-
393 based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-50.
- 394 34. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of
395 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults
396 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 2020:1979-93.
- 397 35. Voysey M, Clemens SAC, Madhi SA, et al. Single-dose administration and the
398 influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1
399 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet
400 2021;397:881-91.

401 36. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S
402 Vaccine for COVID-19. JAMA 2021;325:1535-44.

403 **On behalf of the SWITCH research group**

404

405 **Erasmus MC**

406 N. Tjon

407 K. van Grafhorst

408 L.P.M. van Leeuwen

409 S. Bogers

410 F. de Wilt

411 L. Gommers

412 S. Scherbeijn

413 A.C.P. Lamoré

414

415 **Amsterdam UMC**

416 A.M. Harskamp

417 I. Maurer

418 A.F. Girigorie

419 B. D. Boeser-Nunnink

420 M.M. Mangas Ruiz

421

422 **UMCG**

423 R. Akkerman

424 M. Beukema

425 J.J. de Vries-Idema

426 J. Zuidema

427

428 **LUMC**

429 J.A. Vlot

430 P.H. Verbeek -Menken

1 **Figures and Tables belonging to**

2

3 **Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming**

4

5 R.S.G. Sablerolles MD^{1,2}, W.J.R. Rietdijk PhD², A. Goorhuis MD PhD^{3,4}, D.F. Postma MD PhD⁵, Prof. L.G.
6 Visser⁶, D. Geers Msc⁷, K.S. Schmitz MSc⁷, H.M. Garcia Garrido MD³, Prof. M.P.G. Koopmans⁷,
7 V.A.S.H. Dalm MD PhD⁸, N.A. Kootstra PhD⁹, Prof. A.L.W. Huckriede¹⁰, M. Lafeber MD PhD¹, Prof. D.
8 van Baarle^{10,11}, C.H. GeurtsvanKessel MD PhD^{7,†}, R.D. de Vries, PhD^{7,†}, Prof. P.H.M. van der Kuy^{2,†,*} on
9 behalf of the SWITCH research group

10

11 ¹Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

12 ²Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands

13 ³Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam
14 University Medical Centers, Amsterdam, the Netherlands

15 ⁴Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the
16 Netherlands

17 ⁵Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen,
18 Groningen, the Netherlands

19 ⁶Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

20 ⁷Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands

21 ⁸Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of
22 Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands

23 ⁹Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam
24 Infection and Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands


25 ¹⁰Department of Medical Microbiology and Infection Prevention, University Medical Center
26 Groningen, University of Groningen, Groningen, the Netherlands

27 ¹¹Center for Infectious Disease Control, National Institute for Public Health and the Environment,
28 Bilthoven, the Netherlands

29

30 † contributed equally


31 * Corresponding author: P.H.M. van der Kuy, Department of Hospital Pharmacy, Erasmus University
32 Medical Center, Rotterdam, 3015 GD, the Netherlands. E-mail: h.vanderkuy@erasmusmc.nl.



33

34

35 **Figure 1. Study design and per protocol analysis.** Flow diagram with the number of screened HCWs,
 36 randomization groups, follow-up, and inclusions in the per protocol analysis. After screening, a
 37 relatively high number of HCWs (N=140) dropped out for logistic or other reasons. This was mainly
 38 due to the strict schedule (84 days between prime and boost). After randomization, the number of
 39 HCWs who were lost-to-follow up were not statistically significant different across groups (p=0.19).



40

41

42 **Figure 2. SARS-CoV-2-specific humoral responses.** (A) Levels of binding S-specific antibodies at

43 baseline and post booster vaccination in the 4 different groups. LLoD is 4.81 BAU/ml, responder

44 [resp] cut-off is 33.8 BAU/ml (black line), levels >68.3 BAU/ml correlate to neutralizing capacity (red

45 line, based on panel D). Data is presented as min-to-max box plots with individual values, timepoints

46 were compared by Wilcoxon test. Number of participants below responder cut-off is indicated. (B)

47 Individual fold changes were calculated by dividing the post-boost response by the pre-boost

48 response. Data is presented as min-to-max box plots with individual values, groups were compared

49 by Kruskal-Wallis test. (C) Levels of neutralizing antibodies at baseline and post booster vaccination

50 in the 4 different groups. LLoD is 7.7 IU/ml, responder cut-off is set at 28.6 IU/ml. Data is presented


51 as min-to-max box plots with individual values, timepoints were compared by Wilcoxon test.

52 Number of participants below responder cut-off is indicated. (D) Correlation between binding S-

53 specific antibodies and neutralizing antibodies. Spearman $R = 0.83$, $p < 0.001$. Linear regression on

54 log-transformed data was performed ($Y = 2.89 * X - 0.498$), indicating that presence of neutralizing


55 antibodies (>28.6) correlates with a binding antibody level >68.3 (red lines, resp).



56

57

58 **Figure 3. SARS-CoV-2-specific T-cell responses.** (A) IFN- γ levels in plasma after stimulation of whole
59 blood with an overlapping S pool (Ag2, Qiagen) at baseline and post booster vaccination in the 4
60 different groups. LLoD is 0.01 IU/ml, responder cut-off is 0.15 IU/ml. Data is presented as min-to-
61 max box plots with individual values, timepoints were compared by Wilcoxon test. Number of
62 participants below responder cut-off is indicated. (B) Individual fold changes were calculated by
63 dividing the post-booster response by the pre-booster response. Data is presented as min-to-max box
64 plots with individual values, groups were compared by Kruskal-Wallis test.



65

66

67 **Figure 4. Systemic and local reactions after booster vaccination.** Systemic (fatigue, chills, fever,
68 nausea, headache, muscle ache, joint pain) and local (redness, swelling and / or pain at injection site)
69 reactions were monitored in the seven days following boost. P-values for differences between the
70 distribution of adverse events per group can be found in **Supplementary Table 4.**

71 **Table 1. Baseline characteristics.**

		Total N= 434	Ad26.CO2.S/ no boost N= 105	Ad26.CO2.S/ Ad26.CO2.S N= 106	Ad26.CO2.S/ mRNA-1273 N= 112	Ad26.CO2.S/ BNT162b2 N= 111	P-value
Gender	Male	152 (35)	35 (33)	36 (34)	37 (33)	45 (41)	0.61 ⁺
	Female	281 (65)	70 (67)	70 (67)	75 (67)	66 (59)	
Age		40.5 [30.0-50.0]	41.0 [30.0-51.0]	41.0 [31.0-51.0]	40.5 [30.8-49.0]	38.0 [29.0-47.0]	0.50 [^]
		23.9 [21.6-26.6]	24.2 [22.0-27.5]	23.4 [21.2-26.2]	24.1 [21.7-26.5]	23.8 [21.9-26.0]	0.42 [^]
Ethnicity	BMI	26.6	24.2 [22.0-27.5]	23.4 [21.2-26.2]	24.1 [21.7-26.5]	26.0	0.42 [^]
	African	1 (<1)	1 (1)	0 (0)	0 (0)	0 (0)	0.99 ⁺
	Asian	15 (3)	3 (3)	4 (4)	4 (4)	4 (4)	
	European	403 (93)	95 (90)	98 (92)	105 (94)	105 (95)	
	North-american	2 (<1)	1 (1)	1 (1)	0 (0)	0 (0)	
	South-american	3 (1)	1 (1)	1 (1)	1 (1)	0 (0)	
	Other	10 (2)	4 (4)	2 (2)	2 (2)	2 (2)	
	Current job in hospital	Administrative/policy maker	80 (18)	18 (17)	22 (21)	24 (21)	16 (14)
	Medical doctor	20 (5)	3 (3)	4 (4)	4 (4)	9 (8)	
	Facility services	19 (4)	4 (4)	6 (6)	4 (4)	5 (5)	
	Management	42 (10)	13 (12)	10 (9)	10 (9)	9 (8)	
	Supportive staff clinic/ED	4 (1)	1 (1)	1 (1)	1 (1)	1 (1)	
	Supportive staff outpatient clinic	2 (<1)	0 (0)	2 (2)	0 (0)	0 (0)	
	Researcher	162 (37)	42 (40)	39 (37)	43 (38)	38 (34)	
	Nurse	9 (2)	2 (2)	1 (1)	4 (4)	2 (2)	
	Other	96 (22)	22 (21)	21 (20)	22 (20)	31 (28)	
Comorbidities	Cardiovascular diseases	9 (2)	4 (4)	0 (0)	2 (2)	3 (3)	0.21 ⁺
	Pulmonary diseases	11 (3)	4 (4)	2 (2)	1 (1)	4 (4)	0.45 ⁺
	Diabetes mellitus	2 (<1)	0 (0)	1 (1)	1 (1)	0 (0)	0.87 ⁺
	Liver diseases	2 (<1)	0 (0)	1 (1)	1 (1)	0 (0)	0.87 ⁺
	Kidney diseases	2 (<1)	0 (0)	2 (2)	0 (0)	0 (0)	0.12 ⁺

Performed (self-)tests, prior to SV1	Yes	152 (35)	32 (30)	45 (42)	36 (32)	39 (35)	0.28 ⁺
Performed (self-)tests, between SV1 and SV2	Yes	46 (11)	11 (10)	10 (9)	6 (5)	19 (17)	0.04 ⁺
Time between first vaccination and SV1		94.0 [86.0-98.0]	91.0 [86.0-99.0]	95.0 [88.0-97.0]	96.0 [86.0-98.0]	89.0 [85.0-96.0]	0.10 [^]
Time between SV1 and SV2		28.0 [28.0-28.0]	28.0 [28.0-28.0]	28.0 [28.0-28.0]	28.0 [28.0-28.0]	28.0 [28.0-28.0]	0.07 [^]
Present medication	Present medication use	127 (29)	26 (25)	36 (34)	28 (25)	37 (33)	0.27 ⁺

Note: Values are number (percentage) for categorical variables and median [interquartile range] for continuous variables. SV1= study visit 1 (prior to second vaccination); SV2 = study visit 2 (potential second vaccination); ED=Emergency Department. [^]p-value based on non-parametric test (Kruskal-Wallis) test; ⁺ p-value based on Fisher's exact test.